These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 31755465)

  • 1. Case report: Bilateral uveitis and papillitis secondary to treatment with pembrolizumab.
    Navarro-Perea C; Garcia-Gonzalez J; Perez-Blazquez E
    Indian J Ophthalmol; 2019 Dec; 67(12):2075-2077. PubMed ID: 31755465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vision loss with pembrolizumab treatment: A report of two cases.
    Telfah M; Whittaker TJ; C Doolittle G
    J Oncol Pharm Pract; 2019 Sep; 25(6):1540-1546. PubMed ID: 30997872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A case of bilateral uveitis and papillitis in a patient treated with pembrolizumab.
    Abu Samra K; Valdes-Navarro M; Lee S; Swan R; Foster CS; Anesi SD
    Eur J Ophthalmol; 2016 Apr; 26(3):e46-8. PubMed ID: 26692064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BILATERAL CHOROIDAL DETACHMENTS SECONDARY TO IPILIMUMAB AND PEMBROLIZUMAB USE.
    O'Bryhim BE; Sychev Y; Rao PK
    Retin Cases Brief Rep; 2021 May; 15(3):230-233. PubMed ID: 30044269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Rare Case of Pembrolizumab-Induced Uveitis in a Patient with Metastatic Melanoma.
    Hanna KS
    Pharmacotherapy; 2016 Nov; 36(11):e183-e188. PubMed ID: 27716999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of Chronic Hypotony Following Bilateral Uveitis in a Patient Treated with Pembrolizumab for Cutaneous Metastatic Melanoma.
    Reid G; Lorigan P; Heimann H; Hovan M
    Ocul Immunol Inflamm; 2019; 27(6):1012-1015. PubMed ID: 29672247
    [No Abstract]   [Full Text] [Related]  

  • 7. Photopsias in the Setting of Nivolumab Therapy.
    Ahluwalia A; Kohli AA
    J Neuroophthalmol; 2021 Mar; 41(1):e25-e26. PubMed ID: 32108668
    [No Abstract]   [Full Text] [Related]  

  • 8. Bilateral Drug-Induced Uveitis and Epiretinal Membrane during the Treatment of a Metastatic Cutaneous Melanoma.
    Mozo Cuadrado M; Tabuenca Del Barrio L; Compains Silva E
    Ocul Immunol Inflamm; 2021 Apr; 29(3):543-545. PubMed ID: 31755788
    [No Abstract]   [Full Text] [Related]  

  • 9. Behcet's-like syndrome following pembrolizumab: An immune-related adverse event associated with programmed death receptor-1 inhibitor therapy.
    Thomas S; Bae C; Joy-Ann T; Traverse W
    J Oncol Pharm Pract; 2020 Jun; 26(4):995-999. PubMed ID: 31575354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lupus-like cutaneous reaction following pembrolizumab: An immune-related adverse event associated with anti-PD-1 therapy.
    Shao K; McGettigan S; Elenitsas R; Chu EY
    J Cutan Pathol; 2018 Jan; 45(1):74-77. PubMed ID: 29028121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy?
    Diem S; Keller F; Rüesch R; Maillard SA; Speiser DE; Dummer R; Siano M; Urner-Bloch U; Goldinger SM; Flatz L
    J Immunother; 2016; 39(9):379-382. PubMed ID: 27662340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BILATERAL SEROUS RETINAL DETACHMENT AND UVEITIS ASSOCIATED WITH PEMBROLIZUMAB TREATMENT IN METASTATIC MELANOMA.
    de Vries EW; Schauwvlieghe AS; Haanen JB; de Hoog J
    Retin Cases Brief Rep; 2022 Jul; 16(4):430-434. PubMed ID: 32243282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inflammatory Myopathy and Axonal Neuropathy in a Patient With Melanoma Following Pembrolizumab Treatment.
    Diamantopoulos PT; Tsatsou K; Benopoulou O; Anastasopoulou A; Gogas H
    J Immunother; 2017; 40(6):221-223. PubMed ID: 28498142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune checkpoint blocker-related sarcoid-like granulomatous inflammation: a rare adverse event detected in lymph node aspiration cytology of patients treated for advanced malignant melanoma.
    Rodriguez EF; Lipson E; Suresh K; Cappelli LC; Monaco SE; Maleki Z
    Hum Pathol; 2019 Sep; 91():69-76. PubMed ID: 31279873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uveitis induced by programmed cell death protein 1 inhibitor therapy with nivolumab in metastatic melanoma patient.
    Kanno H; Ishida K; Yamada W; Nishida T; Takahashi N; Mochizuki K; Mizuno Y; Matsuyama K; Takahashi T; Seishima M
    J Infect Chemother; 2017 Nov; 23(11):774-777. PubMed ID: 28527652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pembrolizumab-Associated Optic Neuritis With an Unusual Manifestation of Monocular Optic Disc Edema.
    Teodorescu R; Liu H; Sadun AA
    J Neuroophthalmol; 2024 Jun; 44(2):e246-e248. PubMed ID: 36728538
    [No Abstract]   [Full Text] [Related]  

  • 17. Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients.
    Nguyen BH; Kuo J; Budiman A; Christie H; Ali S
    Melanoma Res; 2017 Apr; 27(2):152-154. PubMed ID: 27776019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab.
    Acero Brand FZ; Suter N; Adam JP; Faulques B; Maietta A; Soulières D; Blais N
    J Immunother Cancer; 2018 Mar; 6(1):22. PubMed ID: 29548299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pembrolizumab-related Bilateral Ocular Hypotony, Uveitis, Cataracts, Exudative Retinal, and Choroidal Detachments: An Unusual Success Story.
    Golash V; Almeida G
    J Immunother; 2020; 43(9):283-285. PubMed ID: 32740318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-1 inhibitor induced alopecia areata.
    Guidry J; Brown M; Medina T
    Dermatol Online J; 2018 Dec; 24(12):. PubMed ID: 30677804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.